Role of Cytoreductive Nephrectomy in mRCC

EP. 1: Role of Cytoreductive Nephrectomy in mRCC

April 14th 2020

EP. 2: Cytoreductive Nephrectomy in mRCC: Current Data

April 14th 2020

EP. 3: Cytoreductive Nephrectomy After I/O in mRCC

April 14th 2020

EP. 4: Ipilimumab/Nivolumab in First-Line mRCC

April 14th 2020

EP. 5: iRECIST Criteria and First-Line Treatment of mRCC

April 14th 2020

EP. 6: Ipilimumab/Nivolumab for Favorable-Risk mRCC

April 14th 2020

EP. 7: SBRT in Combination With Ipilimumab/Nivolumab in mRCC

April 14th 2020

EP. 8: VEGF-TKI Therapy in First-Line mRCC

April 14th 2020

EP. 9: IMDC Criteria and Targeted Therapy in mRCC

April 14th 2020

EP. 10: mRCC: Resistance to VEGF and I/O

April 14th 2020

EP. 11: Second-Line Therapy After I/O in mRCC

April 14th 2020

EP. 12: VEGF TKI Therapy After I/O in mRCC

April 14th 2020

EP. 13: Combination Therapies to Overcome Resistance in mRCC

April 14th 2020

EP. 14: Progress in First-Line mRCC

April 14th 2020

EP. 15: Promising Second-Line Therapies for mRCC

April 14th 2020

EP. 16: Other Trials of Interest in Renal Cancers

April 14th 2020